Section 4 of 6
Clinical evidence
323 evidence topics · 46 sources
Study summaries
AMPLITUDE
Objective
Purpose stated in the ClinicalTrials.gov brief summary
Main objective in the EU Clinical Trials Information System record
Scope and secondary objectives of Part A and Part B in the EU register record
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2022-03-30” (opens the source at this quote in a new tab)
“Primary Completion (Estimated) 2028-06-02” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2030-05-07” (opens the source at this quote in a new tab)
“First Posted 2022-04-06” (opens the source at this quote in a new tab)
“Last Update Posted 2026-10-26” (opens the source at this quote in a new tab)
“Active, not recruiting” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Study locations by country in the ClinicalTrials.gov record
EU member states, trial start, and estimated end of trial in the EU Clinical Trials Information System record
“Locations Belgium, France” (opens the source at this quote in a new tab)
“Start of trial 25/10/2022” (opens the source at this quote in a new tab)
“Estimated end of trial date in EU/EEA: 31/05/2028” (opens the source at this quote in a new tab)
“Estimated global end date of the trial: 31/05/2028” (opens the source at this quote in a new tab)
Recruitment end in the EU member states
First authorization and status by country in the earlier EU Clinical Trials Register record
Number of open sites stated by the company in 2023 and 2024
Countries in the phase 3 portion stated in the design abstract
Study design
Design details in the ClinicalTrials.gov record
“Primary Purpose : Treatment” (opens the source at this quote in a new tab)
“Allocation : Randomized” (opens the source at this quote in a new tab)
“Interventional Model : Sequential Assignment” (opens the source at this quote in a new tab)
“Masking : Quadruple” (opens the source at this quote in a new tab)
Integrated phase 2 and phase 3 trial in the EU Clinical Trials Information System record
Single pivotal adaptive trial with a phase 2 dose-selection portion
Phase 2 portion: two doses or placebo for 12 weeks
Dose selection for phase 3 by the independent data monitoring committee
Pediatric cohort: adolescents aged 10 to 17 years added to the phase 3 portion
Pre-planned interim analysis at week 48 in a pre-specified number of participants
Part B open-label extension: 96 additional weeks of inaxaplin
Final analysis triggered by follow-up duration and number of composite outcomes
Independent data monitoring committee in the ClinicalTrials.gov data summarized by the EU register mirror
Eligibility criteria
Key inclusion and exclusion criteria in the ClinicalTrials.gov record
“APOL1 genotype of G1/G1, G2/G2, or G1/G2” (opens the source at this quote in a new tab)
“Proteinuric kidney disease” (opens the source at this quote in a new tab)
“Solid organ or bone marrow transplant” (opens the source at this quote in a new tab)
“Uncontrolled hypertension” (opens the source at this quote in a new tab)
“History of diabetes mellitus” (opens the source at this quote in a new tab)
Ages and sexes eligible in the ClinicalTrials.gov record
Part A inclusion criteria: genotype, age, body size, proteinuria, and kidney function in the EU register record
Part A inclusion criteria: stable background therapy in the EU register record
Part A exclusion criteria in the EU register record
Part B inclusion and exclusion criteria in the EU register record
Eligibility summarized in the 2025 design abstract
Original eligibility at trial start: ages 18 to 60 years
Population described by the company: severe proteinuria and no comorbidities causing kidney disease
Treatment
Arms and interventions in the ClinicalTrials.gov record
Phase 3 dose: inaxaplin 45 mg once daily or placebo added to standard of care
Investigational medicinal product and placebo in the EU register record
| Field | Quoted record |
|---|---|
| Test product | “VX-147 film-coated tablet” |
| Maximum daily dose | “45 mg milligram(s)” |
| Maximum total dose | “4860 mg milligram(s)” |
| Maximum duration of treatment | “108 week(s)” |
| Orphan designation number | “EMA/OD/0000090156” |
| Placebo | “VX-147, Coated Placebo Tablet” |
Phase 2 portion: two inaxaplin doses or placebo for 12 weeks
Study outcomes
Rationale for using percent change in UPCR at week 48 and eGFR slope as the primary endpoints
Registered primary outcome measures in the ClinicalTrials.gov record
Registered secondary outcome measures in the ClinicalTrials.gov record
Primary and secondary end points in the EU register record
Final analysis: eGFR slope primary endpoint and composite clinical outcome secondary endpoint
Interim analysis endpoints as first described: eGFR slope supported by proteinuria
Interim analysis endpoints in the design abstract: UPCR and eGFR slope
Discussions with the FDA on the accelerated approval pathway
Interim analysis as the basis for an accelerated approval application
GFR slope as a surrogate endpoint: individual participant data meta-analysis of 66 studies
“Treatment effects on the clinical endpoint were strongly associated with treatment effects on total slope (median R2=0.97 [95% Bayesian credible interval [BCI] 0.82 to 1.00]), and moderately associated with those on chronic slope (R2=0.55 [95% BCI 0.25 to 0.77]). There was no evidence of heterogeneity across disease. Our results support use of total slope as a primary endpoint for clinical trials of CKD progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The slope of the meta-regression line is −0.35 (95% BCI −0.42 to −0.29) per mL/min per 1.73 m2/year), indicating that a 0.75 ml/min per 1.73 m2/year greater beneficial effect of the treatment on the total GFR slope is associated with an average 23.3% lower hazard ratio for the clinical end point (95% BCI 19.3% to 27.2%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Albuminuria and GFR slope as end points: NKF workshop with the FDA and EMA
“The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) are currently willing to consider a 30% to 40% glomerular filtration rate (GFR) decline as a surrogate end point for kidney failure for clinical trials of kidney disease progression under appropriate conditions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We conclude that both early change in albuminuria and GFR slope fulfill criteria for surrogacy for use as end points in clinical trials for chronic kidney disease progression under certain conditions, with stronger support for change in GFR than albuminuria.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
GFR slope qualified by the EMA as a validated surrogate endpoint when clinical endpoints are not feasible
Proteinuria reduction as a reasonably likely surrogate end point for accelerated approval: Kidney Health Initiative
“In the United States, reasonably likely surrogate end points can be used as a basis for accelerated approval of therapies intended to treat serious or life-threatening conditions, such as IgAN. The clinical benefit of products approved under this program would need to be verified in a postmarketing confirmatory trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proteinuria as an endpoint in focal segmental glomerulosclerosis: Kidney Health Initiative
“Available data support the use of complete remission of proteinuria in patients with heavy proteinuria as a surrogate endpoint for progression to kidney failure. While substantial treatment effects on proteinuria that are short of a complete remission may also predict the effect of a treatment on progression to kidney failure, further work is needed to determine how such an endpoint should be defined.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proteinuria reduction and kidney survival in steroid-resistant focal segmental glomerulosclerosis
“A 1 unit reduction in log-transformed urinary protein:creatinine ratio was associated with a 3.90 ml/year rise in eGFR (95% CI=2.01 to 5.79).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was an analogous relationship between time-varying proteinuria and time to end-stage kidney disease: the HR for ESKD or death per 1 unit reduction in log-transformed urinary protein-creatinine ratio was 0.23 (95% CI=0.12 to 0.44).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Albuminuria change as a surrogate endpoint across 48 randomized trials
“Across all trials, each 30% reduction in the geometric mean of the UACR in the treatment group relative to the control group was associated with an average of 19% lower hazard for the clinical endpoint (95% Bayesian credible interval (BCI): 5-30%); median coefficient of determination (R2) = 0.66 (95% BCI: 0.06-0.98).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Albuminuria change as a surrogate endpoint in APOL1-mediated kidney disease: real-world cohort preprint
“However, proteinuria has not been evaluated in Apolipoprotein L1 (APOL1)-mediated kidney disease (AMKD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It was estimated that a 50% reduction of UACR at 12 months was associated with a 28% reduction in the kidney composite endpoint (adjusted hazard ratio [aHR]=0.72; 95% confidence interval [CI]:0.59−0.88; p=0.002), and a 38% reduction in the risk of ESKD (aHR=0.62; 95% CI:0.49−0.80; p<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Changes in UACR at 12 months significantly modify the rate of decline of GFR over 24 months and clinically meaningful endpoints, supporting the use of UACR changes as surrogate endpoint in AMKD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Regulatory precedent in focal segmental glomerulosclerosis: FDA approval to reduce proteinuria
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment in the phase 2 and phase 3 portions
Actual enrollment in the ClinicalTrials.gov record
Interim analysis cohort: a pre-specified number of participants at week 48
Number of composite clinical outcomes required for the final analysis
Description of analysis sets
Interim analysis after the interim analysis cohort reaches 48 weeks of treatment
Interim analysis cohort limited to participants with primary AMKD
Duration of eGFR data at the interim and final analyses
Final analysis timing in the design abstract
Results
Participant disposition
APOL1 genotyping study used to identify candidates: interim analysis
Completion of enrollment in the phase 2 dose-ranging portion
Completion of enrollment in the interim analysis cohort in September 2025
Completion of full enrollment in 2026
Enrollment and recruitment status in the ClinicalTrials.gov record
Baseline characteristics
Phase 2 portion: APOL1 genotype, age, and eGFR of 64 dosed participants
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary: study limitations
As of November 2026, no efficacy or safety results of AMPLITUDE have been published or posted: the registry record shows 522 participants enrolled, and the company states that data from the week 48 interim analysis are expected in early 2027. The only participant-level data reported are the APOL1 genotype distribution, mean age (42.7 years), and mean eGFR (42.8 mL/min/1.73 m2) of the 64 participants dosed as of the 2025 abstract; the dose-selection results of that portion and its safety data have not been reported. The accelerated approval pathway rests on the week 48 interim analysis of percent change in UPCR and eGFR slope, two surrogate endpoints; the final analysis of eGFR slope requires at least 2 years of eGFR data, and the composite clinical outcome (sustained eGFR decline of at least 30%, end-stage kidney disease, or death) is a secondary endpoint. The supporting surrogate-endpoint evidence comes mainly from other kidney diseases: the EMA notes that for rare diseases “support of efficacy may need to be provided by additional endpoints”, a 2025 review states for proteinuria short of complete remission in FSGS that “further work is needed to determine how such an endpoint should be defined”, and the only analysis specific to APOL1-mediated kidney disease is a real-world analysis of 128 participants. Eligibility required UPCR of 0.7 to less than 10 g/g and eGFR of 25 to less than 75 mL/min/1.73 m2 and excluded people with diabetes, transplantation, uncontrolled hypertension, or another known cause of kidney disease, so the results will not describe people with modest proteinuria or type 2 diabetes, whom the company describes as “populations not being studied in the AMPLITUDE trial”. The registered age range differs between records: the ClinicalTrials.gov record lists 10 to 65 years, and the EU register inclusion criteria list 12 to 65 years for phase 3. The registry lists 314 locations in 13 countries and territories, including the United States. In Part B, participants who complete Part A receive inaxaplin for an additional 96 weeks without a placebo group, and the definitions of the analysis populations have not been published.
Populations not studied in AMPLITUDE
Surrogacy of GFR slope in rare diseases may need support from additional endpoints
Accelerated approval requires verification of clinical benefit
VX19-147-101
Objective
Purpose stated in the ClinicalTrials.gov brief summary
Primary, secondary, and exploratory objectives in the protocol
Aim of part A and part B in the published report
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2020-06-08” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2021-11-11” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2021-12-09” (opens the source at this quote in a new tab)
“Results First Posted 2023-07-10” (opens the source at this quote in a new tab)
Registered locations
Sites, countries, and enrollment period in the published report
Study design
Single-group, open-label, two-part design
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Phase | “Phase 2” |
| Enrollment | “16” |
Cohorts defined by proteinuria at screening in the protocol
Part B off-treatment follow-up
Rationale for omitting a placebo group and for the 13-week duration
Study design and oversight
Eligibility criteria
Key eligibility criteria in the published report
Key inclusion and exclusion criteria in the ClinicalTrials.gov record
“APOL1 genotype of G1/G1, G2/G2, or G1/G2” (opens the source at this quote in a new tab)
“FSGS diagnosed by kidney biopsy” (opens the source at this quote in a new tab)
“Evidence of non-APOL1-mediated FSGS” (opens the source at this quote in a new tab)
“Participants with known sickle cell disease” (opens the source at this quote in a new tab)
“Solid organ or Bone marrow transplant” (opens the source at this quote in a new tab)
“18 Years to 65 Years (Adult, Older Adult )” (opens the source at this quote in a new tab)
Inclusion criteria in the protocol: biopsy, stable background therapy, eGFR, and UPCR
Exclusion criteria in the protocol: non-APOL1 causes of FSGS and other conditions
Treatment
Intervention in the ClinicalTrials.gov record
Rationale for the 15 mg and 45 mg doses
Restricted medications and foods in the protocol
Study outcomes
Rationale for using percent change in UPCR as the primary endpoint
Registered primary and secondary outcome measures
“Percent Change From Baseline in UPCR” (opens the source at this quote in a new tab)
“From Baseline up to Week 13” (opens the source at this quote in a new tab)
“Maximum Observed Concentration (Cmax) of VX-147” (opens the source at this quote in a new tab)
“Observed Pre-dose Concentration (Ctrough) of VX-147” (opens the source at this quote in a new tab)
Exploratory endpoints in the protocol
Sponsor rationale for UPCR as the primary endpoint and its measurement
Proteinuria and progression to end-stage kidney disease
Threshold for a clinically meaningful reduction in proteinuria
Placebo response in proteinuric CKD trials
Commentary on proteinuria reduction as an endpoint
“The degree of proteinuria reduction achieved in the phase 2A clinical trial has been shown to be associated with slowing the progression of proteinuric kidney disease and it is unlikely to be an artefact of being enrolled in a clinical trial” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment in the protocol
Sample size based on precision of the estimate
Participants enrolled and analyzed
Description of analysis sets
Primary efficacy analysis restricted to participants with at least 80% adherence
Analysis sets defined in the statistical analysis plan
Analysis populations in the posted results
Statistical methods for the primary endpoint: log-transformed geometric mean percent change
Statistical methods: confidence intervals, multiplicity, and sensitivity analyses in the statistical analysis plan
Statistical methods: descriptive safety and pharmacokinetic analyses in the protocol
Results
Participant disposition
Study parts covered by the posted results
Exclusion of participants below the adherence threshold and part B participation
Company statement on noncompliant participants
Baseline characteristics
Demographic and clinical characteristics at baseline (Table 1)
| Characteristic | Total (N=16) | Nephrotic-range proteinuria (N=3) | Subnephrotic-range proteinuria (N=13) |
|---|---|---|---|
| Age, years, mean ±SD | “38.8±14.5” | “45.0±10.5” | “37.3±15.2” |
| Male, no. (%) | “7 (44)” | “1 (33)” | “6 (46)” |
| Female, no. (%) | “9 (56)” | “2 (67)” | “7 (54)” |
| APOL1 genotype G1/G1, no. (%) | “9 (56)” | “3 (100)” | “6 (46)” |
| APOL1 genotype G2/G2, no. (%) | “1 (6)” | “0” | “1 (8)” |
| APOL1 genotype G1/G2, no. (%) | “6 (38)” | “0” | “6 (46)” |
| Body-mass index, mean ±SD | “29.6±6.4” | “32.7±6.4” | “28.9±6.4” |
| Urinary protein-to-creatinine ratio, mean ±SD | “2.08±0.90” | “3.47±1.07” | “1.77±0.49” |
| Estimated GFR, ml/min/1.73 m2, mean ±SD | “51.2±14.0” | “51.4±22.2” | “51.2±12.8” |
| ACE inhibitor ≥28 days before day 1, no. (%) | “8 (50)” | “1 (33)” | “7 (54)” |
| Angiotensin-receptor blocker ≥28 days before day 1, no. (%) | “7 (44)” | “3 (100)” | “4 (31)” |
| Immunosuppressants ≥28 days before day 1, no. (%) | “4 (25)” | “1 (33)” | “3 (23)” |
Baseline UPCR in the efficacy population and similarity across subgroups
Efficacy results
Primary endpoint: percent change from baseline in UPCR at week 13 (Table 2)
| Measure | Total (N=13) | Nephrotic-range proteinuria (N=3) | Subnephrotic-range proteinuria (N=10) |
|---|---|---|---|
| Mean UPCR at baseline, ±SD | “2.21±0.95” | “3.47±1.07” | “1.84±0.52” |
| Mean UPCR at week 13, ±SD | “1.27±0.73” | “1.83±0.58” | “1.10±0.71” |
| Geometric percent change from baseline at week 13 (95% CI) | “−47.6 (−60.0 to −31.3)” | “−47.7 (−70.1 to −8.5)” | “−47.5(−63.4 to −24.6)” |
Primary endpoint in the published abstract
Time course of proteinuria reduction
Analysis of all 16 participants regardless of adherence
Pharmacokinetics: AUC0-24h at week 5 (secondary outcome)
| Measure | Quoted record |
|---|---|
| Outcome measure | “Area Under the Concentration Time-curve From 0 to 24 Hours (AUC0-24hr) of VX-147” |
| Time frame | “Pre-dose and at 0.25, 0.5, 1, 2, 4, 12 and 24 hours Post-dose on Week 5” |
| Overall number of participants analyzed | “13” |
| Mean (standard deviation), h*mcg/mL | “15.3(6.37)” |
Company statement of the primary endpoint result
Health-related quality of life and patient-reported outcomes
SF-36 planned as an exploratory endpoint
SF-36 results
No evidence found.
Safety results
Overview of adverse events
Adverse events (Table 3)
| Event, no. (%) | Total (N=16) | Nephrotic-range proteinuria (N=3) | Subnephrotic-range proteinuria (N=13) |
|---|---|---|---|
| Any adverse event | “15 (94)” | “3 (100)” | “12 (92)” |
| Mild | “7 (44)” | “1 (33)” | “6 (46)” |
| Moderate | “8 (50)” | “2 (67)” | “6 (46)” |
| Serious adverse event | “1 (6)” | “0” | “1 (8)” |
| Headache | “4 (25)” | “1 (33)” | “3 (23)” |
| Back pain | “3 (19)” | “0” | “3 (23)” |
| Nausea | “3 (19)” | “1 (33)” | “2 (15)” |
| Decrease in blood bicarbonate level | “2 (12)” | “0” | “2 (15)” |
| Diarrhea | “2 (12)” | “1 (33)” | “1 (8)” |
| Dizziness | “2 (12)” | “0” | “2 (15)” |
| Dyspepsia | “2 (12)” | “0” | “2 (15)” |
| Fatigue | “2 (12)” | “0” | “2 (15)” |
Laboratory values, electrocardiograms, vital signs, and eGFR
Deaths, serious adverse events, and other adverse events in the posted results
| Measure, affected / at risk (%) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| All-cause mortality | “0/3 (0.00%)” | “0/13 (0.00%)” | “0/16 (0.00%)” |
| Serious adverse events, total | “0/3 (0.00%)” | “1/13 (7.69%)” | “1/16 (6.25%)” |
| Other (not including serious) adverse events, total | “3/3 (100.00%)” | “12/13 (92.31%)” | “15/16 (93.75%)” |
Adverse events in investigations and cardiac disorders in the posted results
| Event | Total, affected / at risk (%) |
|---|---|
| Blood bicarbonate decreased | “2/16 (12.50%)” |
| Blood creatine phosphokinase increased | “1/16 (6.25%)” |
| Electrocardiogram ST segment depression | “1/16 (6.25%)” |
| Gamma-glutamyltransferase increased | “1/16 (6.25%)” |
| Transaminases increased | “1/16 (6.25%)” |
| Palpitations | “1/16 (6.25%)” |
Study limitations
Summary: study limitations
VX19-147-101 was a single-group, open-label study without a placebo group; the protocol states that a placebo arm was omitted because of a “very low likelihood of spontaneous remission”. Sixteen participants were enrolled, and the primary analysis included the 13 participants with at least 80% adherence; the planned sample size of 10 was chosen for the precision of the geometric mean estimate, without a power calculation. Treatment lasted 13 weeks, and the off-treatment follow-up (part B) included 9 participants. The primary endpoint was the percent change from baseline in the urinary protein-to-creatinine ratio at week 13, and the secondary endpoints were safety and pharmacokinetics. Eligibility required biopsy-proven focal segmental glomerulosclerosis, two APOL1 variants, age 18 to 65 years, and an estimated GFR of at least 30 mL/min/1.73 m2 (±10%), so other APOL1-mediated kidney disease phenotypes were not studied; only 3 participants had nephrotic-range proteinuria. All 16 participants were Black or African American and were enrolled at sites in France, the United Kingdom, and the United States. The protocol listed SF-36 as an exploratory endpoint, and no SF-36 results were located in the published report or the posted results.
Limitations stated by the investigators
Other APOL1-mediated kidney disease phenotypes not studied
Commentary: lack of randomization, population, and endpoint
“First, this is not a randomized control trial, there is therefore a need for a phase 3 clinical trial of inaxaplin + standard of care versus placebo + standard of care before clinical use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second, the study was carried out in a small population of participants from Europe and North America.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This point is especially important since Africans living in Africa were not part of this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Third, reduction in proteinuria was used as the primary end point for this study” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AMPLIFIED
Objective
Aim stated in the design abstract
Populations outside the pivotal trial stated by the company
Planned study announced by the company
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2025-02-04” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2026-07-20” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2026-07-20” (opens the source at this quote in a new tab)
“First Posted 2025-01-27” (opens the source at this quote in a new tab)
“Last Update Posted 2026-08-20” (opens the source at this quote in a new tab)
“Completed” (opens the source at this quote in a new tab)
“No Results Posted” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Study locations by state in the ClinicalTrials.gov record
Completion of enrollment reported in the first quarter 2026 results
Completion of enrollment and dosing reported in the second quarter 2026 results
Study design
Official title in the ClinicalTrials.gov record
Design details in the ClinicalTrials.gov record
| Field | Registry value |
|---|---|
| Study type | “Interventional” |
| Phase | “Phase 2” |
| Primary purpose | “Treatment” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
Single-arm, open-label design with two reported cohorts
Eligibility criteria
Key inclusion and exclusion criteria in the ClinicalTrials.gov record
Age, sex, and healthy volunteers in the ClinicalTrials.gov record
| Field | Registry value |
|---|---|
| Ages eligible for study | “18 Years to 67 Years” |
| Sexes eligible for study | “All” |
| Accepts healthy volunteers | “No” |
Proteinuria thresholds by cohort in the design abstract
Proteinuria thresholds by cohort stated with the results
Treatment
Arm and intervention in the ClinicalTrials.gov record
Dose and background therapy stated with the results
Study outcomes
Rationale for using percent change in UACR as the primary endpoint
Registered primary and secondary outcome measures in the ClinicalTrials.gov record
Primary and other endpoints stated with the results
Albuminuria change as a surrogate endpoint across 48 randomized trials
“Here, in an individual participant data analysis of 48 randomized controlled trials (studies) involving 85,681 participants, we assessed the association between treatment effects on 6-month urinary albumin:creatinine ratio (UACR) change and the established clinical endpoint of kidney failure or doubling of serum creatinine concentrations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Across all trials, each 30% reduction in the geometric mean of the UACR in the treatment group relative to the control group was associated with an average of 19% lower hazard for the clinical endpoint (95% Bayesian credible interval (BCI): 5-30%); median coefficient of determination (R2) = 0.66 (95% BCI: 0.06-0.98).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was no clear evidence that this association varied by CKD etiology.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Albuminuria change and kidney outcomes in APOL1-mediated kidney disease
“Recently, proteinuria has been accepted as a surrogate end point for clinical trials in focal segmental glomerulosclerosis (FSGS) ang IgA nephropathy. However, proteinuria has not been evaluated in Apolipoprotein L1 (APOL1)-mediated kidney disease (AMKD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Real world data (RWD) analysis of 128 patients of African ancestry with APOL1 high risk genotypes, without diabetes, enrolled in the Million Veteran Program (MVP; n=109) or the biorepository at Vanderbilt University (BioVU; n=19), who had urine albumin-creatinine ratio (UACR) >= 420 mg/g (PCR~0.9 g/g) with a concurrent GFR value.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It was estimated that a 50% reduction of UACR at 12 months was associated with a 28% reduction in the kidney composite endpoint (adjusted hazard ratio [aHR]=0.72; 95% confidence interval [CI]:0.59−0.88; p=0.002), and a 38% reduction in the risk of ESKD (aHR=0.62; 95% CI:0.49−0.80; p<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Changes in UACR at 12 months significantly modify the rate of decline of GFR over 24 months and clinically meaningful endpoints, supporting the use of UACR changes as surrogate endpoint in AMKD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Conditions under which albuminuria reduction is considered a reasonably likely surrogate
“It was considered that changes in albuminuria may be informative when baseline albuminuria is large and has a dominant role in disease progression and the therapeutic under investigation has a mechanistic relationship to reduce albuminuria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparison with the phase 2a result stated by the company
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Participants dosed and analyzed by cohort stated with the results
| Cohort | Enrolled and dosed | Efficacy analysis | On treatment with a week 13 assessment |
|---|---|---|---|
| Cohort 1: AMKD with modest proteinuria | “N=23” | “N=22” | “18 and 14 people in cohort 1 and 2, respectively” |
| Cohort 2: AMKD with type 2 diabetes | “N=18” | “N=17” | “18 and 14 people in cohort 1 and 2, respectively” |
Description of analysis sets
Efficacy analysis set and week 13 analysis population
Geometric mean percent change by cohort and post hoc confidence intervals
Results
Participant disposition
Participants enrolled, dosed, and excluded from the efficacy analyses
Baseline characteristics
Baseline UACR and UPCR by cohort
| Measure | Cohort 1: AMKD with modest proteinuria | Cohort 2: AMKD with type 2 diabetes |
|---|---|---|
| Mean baseline UACR g/g (standard deviation) | “0.28 (0.09)” | “0.67 (0.87)” |
| Mean baseline UPCR g/g (standard deviation) | “0.46 (0.20)” | “1.12 (1.51)” |
FSGS diagnosis and background kidney therapy
FSGS diagnosis in both cohorts stated on the earnings call
Efficacy results
Percent change in UACR and UPCR at week 13 by cohort
| Endpoint | Cohort 1: AMKD with modest proteinuria | Cohort 2: AMKD with type 2 diabetes |
|---|---|---|
| Primary: geometric mean percent change in UACR at week 13 (95% confidence interval) | “-42.7%”; “(-58.3%, -21.1%)” | “-17.3%”; “(-36.3%, 7.2%)” |
| Other: geometric mean percent change in UPCR at week 13 (95% confidence interval) | “-44.7%”; “(-60.9%, -21.9%)” | “-25.4%”; “(-45.1%, 1.4%)” |
Cohort 1: AMKD with modest proteinuria
Cohort 2: AMKD with type 2 diabetes
Results restated in the third quarter 2026 results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Serious adverse events, severity, headache, and transaminase elevations
Study limitations
Summary: study limitations
AMPLIFIED was a single-arm, open-label study without a placebo or active comparator, so each cohort's result is a change from baseline over 13 weeks of inaxaplin 45 mg once daily added to “optimized standard of care”. Of 41 participants enrolled and dosed (23 in cohort 1 and 18 in cohort 2), 39 were in the efficacy analyses, and the week 13 analyses included 18 and 14 participants; the registry lists an actual enrollment of 42. The 95% confidence intervals “were generated post-hoc”, and in cohort 2 they include no change for both UACR (-36.3% to 7.2%) and UPCR (-45.1% to 1.4%). The design abstract planned 45 participants, including a third cohort of 15 participants with sickle cell disease, HIV, or lupus nephritis, which the results announcement does not report. The registry lists UACR as the only efficacy outcome measure, and UPCR is reported as an “other” endpoint. All 35 registered sites are in the United States, eligibility was limited to ages 18 to 67 years with eGFR of at least 25 mL/min/1.73 m2, and the only baseline characteristics reported are mean UACR and UPCR by cohort. The study measured no kidney function outcome. The AMKD-specific analysis supporting UACR change as a surrogate endpoint used 12-month changes in 128 participants without diabetes and with UACR of at least 420 mg/g, a range that excludes the cohort 1 eligibility range (UACR at least 100 to below 420 mg/g) and the cohort 2 population. As of 2026-11-15 the results are available only from company communications: the registry shows “No Results Posted”, and no peer-reviewed publication or congress presentation of the results was identified.
VX18-147-001
Objective
Aims of the two phase 1 studies
“We conducted two phase 1 studies evaluating the safety, tolerability, and pharmacokinetics of single-ascending doses (SAD) and multiple-ascending doses (MAD) of inaxaplin in healthy participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Herein we report the safety, tolerability, and pharmacokinetics of inaxaplin from two phase 1 single-ascending dose (SAD)/multiple-ascending dose (MAD) studies in healthy participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First-in-human study VX18-147-001
“The first-in-human study of inaxaplin (Study VX18-147-001 or Study 1) evaluated single ascending doses of 7.5 mg up to 50 mg and multiple ascending doses of 15 mg once daily, 15 mg twice daily, or 45 mg once daily in healthy participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary objective: safety and tolerability
“The primary objective for Parts A and B of both phase 1 studies was to determine safety and tolerability based on assessment of adverse events (AEs), clinical laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis), standard 12-lead ECG measures (performed in triplicate), and vital signs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CYP3A4 interaction objective in Study 1
“We assessed the potential of inaxaplin to either induce or inhibit CYP3A4 enzymes in Study 1 by measuring the effect of inaxaplin administration on serum concentrations of midazolam, a sensitive CYP3A4 substrate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Study design
Randomized, double-blind, placebo-controlled SAD/MAD design
Part A single ascending doses and Part B multiple ascending doses
“Part A of both phase 1 studies was designed to evaluate the safety and tolerability of single oral ascending doses of inaxaplin administered to healthy participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Part B of both phase 1 studies was designed to evaluate the safety and tolerability of multiple oral ascending doses of inaxaplin administered to healthy participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Unique participants per cohort and safety follow-up
“All SAD and MAD cohorts included unique participants. There was no cross-over of participants within or across study cohorts. All participants had a Safety Follow-up Visit 7–10 days after the last dose of study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Healthy adults of non-childbearing potential
“In both studies, we enrolled healthy men and women of non-childbearing potential who were at least 18 years of age with body weight of >50 kg and body mass index (BMI) 18.0 to 32.0 kg/m2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“was defined by no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, standard 12-lead electrocardiogram (ECG), and clinical laboratory tests.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Single doses of 7.5 to 50 mg or placebo in Part A of Study 1
Multiple doses for 14 days or placebo in Part B of Study 1
Study outcomes
Rationale for using safety and tolerability assessments as the primary endpoints
Primary safety and tolerability endpoints
“The primary objective for Parts A and B of both phase 1 studies was to determine safety and tolerability based on assessment of adverse events (AEs), clinical laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis), standard 12-lead ECG measures (performed in triplicate), and vital signs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetic assessments
“In both studies, we assessed plasma pharmacokinetic (PK) parameter estimates of inaxaplin (i.e., time of maximum concentration [tmax], maximum observed concentration [Cmax], area under the concentration vs. time curve from the time of dosing to 24 h [AUC0–24h], terminal phase half-life [t½], apparent volume of distribution [V/F], and apparent clearance at steady-state [CLss/F]) after multiple oral ascending doses of inaxaplin derived from plasma concentration-time data. We also assessed urine PK parameter estimates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Midazolam as a sensitive CYP3A4 substrate
“We assessed the potential of inaxaplin to either induce or inhibit CYP3A4 enzymes in Study 1 by measuring the effect of inaxaplin administration on serum concentrations of midazolam, a sensitive CYP3A4 substrate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Participants randomized and dosed across both studies
“One hundred and seventy eight participants were randomized and received at least one dose of study drug in the SAD and MAD cohorts of the two phase 1 studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were 21 participants who received placebo in the SAD cohort and 23 participants who received placebo in the MAD cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were 63 participants who received inaxaplin in the SAD cohort and 71 participants who received inaxaplin in the MAD cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants per group in the MAD cohorts of Study 1
“Inaxaplin 15 mg once daily (N = 9)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inaxaplin 15 mg twice daily (N = 9)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inaxaplin 45 mg once daily (N = 9)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Placebo is pooled from all MAD cohorts in Study 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Safety set and descriptive analyses
“N, Safety Set sample size” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This table includes all participants in the MAD cohorts of Study 1 who received at least one dose of study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In both phase 1 studies, we used descriptive analyses on safety data including AEs, clinical laboratory assessments, vital signs, and ECGs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Triplicate ECGs and pooled analysis across cohorts
“Since ECGs were performed in triplicate, the mean of each individual ECG parameter measurement (i.e., PR, RR, QRS, QT, QTcF, heart rate) at each specific visit and time point was used as the ECG for that specific visit and time point for summary purposes. In addition to analyses performed in the SAD and MAD cohorts separately for the two studies, we conducted a pooled analysis across cohorts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Discontinuation for papular rash in the 45 mg once daily group of Study 1
Disposition pooled across Study 1 and Study 2
| Disposition | Placebo | Inaxaplin total |
|---|---|---|
| Completed study drug (SAD only), n/N (%) | “21/21 (100.0)”View highlighted excerpt for this quote | “63/63 (100.0)”View highlighted excerpt for this quote |
| Completed study drug (MAD only), n/N (%) | “18/23 (78.3)”View highlighted excerpt for this quote | “50/71 (70.4)”View highlighted excerpt for this quote |
| Discontinued study drug (MAD only), n/N (%) | “5/23 (21.7)”View highlighted excerpt for this quote | “21/71 (29.6)”View highlighted excerpt for this quote |
| Discontinued for adverse event | “0”View highlighted excerpt for this quote | “3/71 (4.2)”View highlighted excerpt for this quote |
| Participant refused further dosing (not due to AE) | “0”View highlighted excerpt for this quote | “1/71 (1.4)”View highlighted excerpt for this quote |
| Other non-adherence | “0”View highlighted excerpt for this quote | “1/71 (1.4)”View highlighted excerpt for this quote |
| Sponsor decision | “5/23 (21.7)”View highlighted excerpt for this quote | “16/71 (22.5)”View highlighted excerpt for this quote |
Baseline characteristics
Demographics pooled across Study 1 and Study 2
Age and comparability of groups
Efficacy results
Dose proportionality and half-life across both studies
“The PK of inaxaplin was generally dose proportional, and the variability in PK parameters was generally low and did not appear to change across the dose range (online Table S1). Half-life was consistent across both studies ranging from approximately 13.3 to 22.9 h, which supports once daily dosing (online Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Renal clearance as a minor excretion pathway
“Renal clearance was a minor excretion pathway for inaxaplin; dose adjustments are therefore not anticipated for the intended patient population which will include patients with renal function impairment (online Table S2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
No clinically significant interaction with midazolam
“There were no clinically significant PK drug-drug interactions between inaxaplin and midazolam (online Table S3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inaxaplin is not a clinically significant inhibitor or inducer of CYP3A4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Adverse events in the MAD cohorts of Study 1
Papular rash leading to discontinuation in Study 1
“One participant in the inaxaplin 45 mg once daily MAD group in Study 1 discontinued treatment due to an AE of papular rash, which was mild in severity, resolved without treatment, and was considered unlikely related to the study drug by the investigator (Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events pooled across Study 1 and Study 2
Severity, relatedness, and headache across both studies
“All AEs were mild or moderate in severity. None of the AEs were considered by the investigator as related to inaxaplin. There were no serious adverse events (SAEs) (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most of these AEs had similar or lower incidences in the inaxaplin group compared to placebo, except for headache (10.4% in the inaxaplin group compared to 2.3% in the placebo group) (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of headache was lower in participants treated with doses of inaxaplin ≤45 mg once daily (11.1%) than in those treated with doses of inaxaplin ≥60 mg once daily (18.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Laboratory values, vital signs, and ECG parameters
“During the course of the SAD and MAD cohorts of both phase 1 studies, no clinically relevant trends were noted in any of the clinical laboratory results. Specifically, mean serum creatinine concentrations, serum lipid profile (i.e., total cholesterol, HDL cholesterol, LDL cholesterol, and triglyceride concentrations), and leukocyte counts were similar between the inaxaplin and placebo groups for all timepoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was no evidence of effects of inaxaplin on ECG parameters. There were no participants with a maximum QT interval corrected by Fridericia’s formula (QTcF; calculated from ECG assessments) interval >480 msec. No participants in the SAD or MAD cohorts had a QTcF interval increase >60 msec.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: study limitations
VX18-147-001 enrolled healthy adults, so its safety findings do not describe people with APOL1-mediated kidney disease. Multiple dosing lasted 14 days, and each MAD group of Study 1 had 9 participants receiving inaxaplin (15 mg once daily, 15 mg twice daily, or 45 mg once daily) and 9 receiving pooled placebo. Across both phase 1 studies, 128 of 134 participants receiving inaxaplin (95.5%) were male, which the authors attribute to the exclusion of women of childbearing potential. The publication reports demographics, disposition, and the overall adverse event table pooled across Study 1 and Study 2, and gives the pharmacokinetic parameter estimates, including the midazolam interaction results, only in online supplementary tables. The trials were designed and funded by Vertex Pharmaceuticals, and four of the authors are Vertex employees who own stock or stock options in the company.
Sponsor funding and employment
“These studies were supported by Vertex Pharmaceuticals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Drs. Ogo Egbuna, George Manos, Simon Tian, and Fanuel Hagos are employees of Vertex Pharmaceuticals and own stock or stock options in the company.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
VX20-147-008
Objective
Aims of the two phase 1 studies
Higher-dose study VX20-147-008
“To provide additional clinical information on the safety of higher doses of inaxaplin, a second phase 1 study of inaxaplin (Study VX20-147-008 or Study 2) evaluated single ascending doses of 90 mg up to 165 mg and multiple ascending doses of 60 mg up to 120 mg once daily in healthy participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary objective: safety and tolerability
“The primary objective for Parts A and B of both phase 1 studies was to determine safety and tolerability based on assessment of adverse events (AEs), clinical laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis), standard 12-lead ECG measures (performed in triplicate), and vital signs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Study design
Randomized, double-blind, placebo-controlled SAD/MAD design
Part A single ascending doses and Part B multiple ascending doses
“Part A of both phase 1 studies was designed to evaluate the safety and tolerability of single oral ascending doses of inaxaplin administered to healthy participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Part B of both phase 1 studies was designed to evaluate the safety and tolerability of multiple oral ascending doses of inaxaplin administered to healthy participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Unique participants per cohort and safety follow-up
“All SAD and MAD cohorts included unique participants. There was no cross-over of participants within or across study cohorts. All participants had a Safety Follow-up Visit 7–10 days after the last dose of study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Healthy adults of non-childbearing potential
“In both studies, we enrolled healthy men and women of non-childbearing potential who were at least 18 years of age with body weight of >50 kg and body mass index (BMI) 18.0 to 32.0 kg/m2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“was defined by no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, standard 12-lead electrocardiogram (ECG), and clinical laboratory tests.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Single doses of 90 to 165 mg or placebo in Part A of Study 2
Multiple doses for 14 days or placebo in Part B of Study 2
Study outcomes
Rationale for using safety and tolerability assessments as the primary endpoints
Primary safety and tolerability endpoints at higher doses
“To provide additional clinical information on the safety of higher doses of inaxaplin, a second phase 1 study of inaxaplin (Study VX20-147-008 or Study 2) evaluated single ascending doses of 90 mg up to 165 mg and multiple ascending doses of 60 mg up to 120 mg once daily in healthy participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary objective for Parts A and B of both phase 1 studies was to determine safety and tolerability based on assessment of adverse events (AEs), clinical laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis), standard 12-lead ECG measures (performed in triplicate), and vital signs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetic assessments
“In both studies, we assessed plasma pharmacokinetic (PK) parameter estimates of inaxaplin (i.e., time of maximum concentration [tmax], maximum observed concentration [Cmax], area under the concentration vs. time curve from the time of dosing to 24 h [AUC0–24h], terminal phase half-life [t½], apparent volume of distribution [V/F], and apparent clearance at steady-state [CLss/F]) after multiple oral ascending doses of inaxaplin derived from plasma concentration-time data. We also assessed urine PK parameter estimates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Participants randomized and dosed across both studies
“One hundred and seventy eight participants were randomized and received at least one dose of study drug in the SAD and MAD cohorts of the two phase 1 studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were 21 participants who received placebo in the SAD cohort and 23 participants who received placebo in the MAD cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were 63 participants who received inaxaplin in the SAD cohort and 71 participants who received inaxaplin in the MAD cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants per group in the completed MAD cohorts of Study 2
“Inaxaplin 60 mg once daily (N = 9)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inaxaplin 90 mg once daily (N = 9)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inaxaplin 120 mg once daily (N = 9)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Placebo is pooled from MAD cohorts in Study 2 (except for the two MAD cohorts that were prematurely discontinued based on sponsor decision).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Safety set excluding the prematurely discontinued MAD cohorts
“N, Safety Set sample size” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This table includes all participants in the MAD cohorts of Study 2 who were not prematurely discontinued and who received at least one dose of study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A summary of AEs for the SAD and MAD cohorts of both phase 1 studies is presented in Table 3; this table includes the two MAD cohorts in Study 2 that were prematurely discontinued by the sponsor due to ECG equipment malfunction and COVID-19 infection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descriptive analyses, triplicate ECGs, and pooled analysis across cohorts
“In both phase 1 studies, we used descriptive analyses on safety data including AEs, clinical laboratory assessments, vital signs, and ECGs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Since ECGs were performed in triplicate, the mean of each individual ECG parameter measurement (i.e., PR, RR, QRS, QT, QTcF, heart rate) at each specific visit and time point was used as the ECG for that specific visit and time point for summary purposes. In addition to analyses performed in the SAD and MAD cohorts separately for the two studies, we conducted a pooled analysis across cohorts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Two MAD cohorts discontinued by sponsor decision
“In the Study 2, 21 participants in two MAD cohorts discontinued treatment due to sponsor decision; this includes 12 participants (inaxaplin 60 mg once daily group: N = 9; placebo group: N = 3) who discontinued study drug due to ECG equipment malfunction and 9 participants (inaxaplin 90 mg once daily group: N = 7; placebo group: N = 2) who discontinued study drug due to the impact of the COVID-19 pandemic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dosing in one cohort (inaxaplin 60 mg once daily MAD group: N = 9; placebo MAD group: N = 3) was paused to investigate an ECG finding in a single participant that was ultimately found to be due to ECG equipment malfunction (dosing was stopped prior to day 2 dose for the incident participant and prior to day 3 dose in all other participants). As dosing was interrupted, the cohort was discontinued per sponsor decision.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to possible exposure to infection, the sponsor decided to discontinue the remainder of the cohort (inaxaplin 90 mg once daily MAD group: N = 7; placebo MAD group: N = 2) on day 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Discontinuations for adverse events in Study 2
“Participant in the inaxaplin 60 mg once daily treatment group discontinued study drug due to an AE of tachycardia; AE was mild in severity and considered by the investigator as not related to study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In Study 2, one participant in the inaxaplin 90 mg once daily MAD group discontinued treatment due to the AE of COVID-19 (as described above), which was moderate in severity, resolved without treatment, and was considered by the investigator as not related to inaxaplin (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disposition pooled across Study 1 and Study 2
| Disposition | Placebo | Inaxaplin total |
|---|---|---|
| Completed study drug (SAD only), n/N (%) | “21/21 (100.0)”View highlighted excerpt for this quote | “63/63 (100.0)”View highlighted excerpt for this quote |
| Completed study drug (MAD only), n/N (%) | “18/23 (78.3)”View highlighted excerpt for this quote | “50/71 (70.4)”View highlighted excerpt for this quote |
| Discontinued study drug (MAD only), n/N (%) | “5/23 (21.7)”View highlighted excerpt for this quote | “21/71 (29.6)”View highlighted excerpt for this quote |
| Discontinued for adverse event | “0”View highlighted excerpt for this quote | “3/71 (4.2)”View highlighted excerpt for this quote |
| Participant refused further dosing (not due to AE) | “0”View highlighted excerpt for this quote | “1/71 (1.4)”View highlighted excerpt for this quote |
| Other non-adherence | “0”View highlighted excerpt for this quote | “1/71 (1.4)”View highlighted excerpt for this quote |
| Sponsor decision | “5/23 (21.7)”View highlighted excerpt for this quote | “16/71 (22.5)”View highlighted excerpt for this quote |
Baseline characteristics
Demographics pooled across Study 1 and Study 2
Age and comparability of groups
Efficacy results
Dose proportionality and half-life up to 120 mg once daily
“The PK of inaxaplin was generally dose proportional, and the variability in PK parameters was generally low and did not appear to change across the dose range (online Table S1). Half-life was consistent across both studies ranging from approximately 13.3 to 22.9 h, which supports once daily dosing (online Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It exhibits dose proportional PK with low variability across doses up to 120 mg once daily for 14 days with a half-life ranging from 13.3 to 22.9 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Renal clearance as a minor excretion pathway
“Renal clearance was a minor excretion pathway for inaxaplin; dose adjustments are therefore not anticipated for the intended patient population which will include patients with renal function impairment (online Table S2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Adverse events in the completed MAD cohorts of Study 2
Adverse events in the two prematurely discontinued MAD cohorts
“In the two MAD cohorts from Study 2 that were prematurely discontinued due to sponsor decision, there were eight AEs including four AEs of headache (one in the placebo group; three in the inaxaplin group), two AEs of COVID-19 (both in the inaxaplin group), one AE of fatigue (placebo group) and one AE of dyspnea (inaxaplin group).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tachycardia leading to discontinuation in Study 2
“One participant in the inaxaplin 60 mg once daily MAD group in Study 2 discontinued treatment due to an AE of tachycardia (Table 5); this participant reported anxiety as an AE (of mild intensity) and reported similar instances of test anxiety in the past. The AE of tachycardia was considered mild in severity, resolved without treatment, and was considered by the investigator as not related to study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events pooled across Study 1 and Study 2
Severity, relatedness, and headache across both studies
“All AEs were mild or moderate in severity. None of the AEs were considered by the investigator as related to inaxaplin. There were no serious adverse events (SAEs) (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inaxaplin was generally well tolerated at single doses up to 165 mg and at multiple doses up to 120 mg once daily for 14 days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of headache was lower in participants treated with doses of inaxaplin ≤45 mg once daily (11.1%) than in those treated with doses of inaxaplin ≥60 mg once daily (18.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Laboratory values, vital signs, and ECG parameters
“During the course of the SAD and MAD cohorts of both phase 1 studies, no clinically relevant trends were noted in any of the clinical laboratory results. Specifically, mean serum creatinine concentrations, serum lipid profile (i.e., total cholesterol, HDL cholesterol, LDL cholesterol, and triglyceride concentrations), and leukocyte counts were similar between the inaxaplin and placebo groups for all timepoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was no evidence of effects of inaxaplin on ECG parameters. There were no participants with a maximum QT interval corrected by Fridericia’s formula (QTcF; calculated from ECG assessments) interval >480 msec. No participants in the SAD or MAD cohorts had a QTcF interval increase >60 msec.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: study limitations
VX20-147-008 enrolled healthy adults at one United States site and tested single doses of 90 to 165 mg and multiple doses of 60 to 120 mg once daily, above the 15 mg and 45 mg once daily doses being evaluated in the phase 2/3 trial, with multiple dosing limited to 14 days. Two of its MAD cohorts were stopped early by sponsor decision: 12 participants after an ECG finding attributed to equipment malfunction and 9 participants because of possible COVID-19 exposure, and both cohorts were repeated with new participants. The Study 2 MAD adverse event table therefore excludes these cohorts and has 9 participants in each dose group and 9 receiving pooled placebo, while the pooled adverse event table includes them. Across both phase 1 studies, 128 of 134 participants receiving inaxaplin (95.5%) were male, which the authors attribute to the exclusion of women of childbearing potential. Pharmacokinetic parameter estimates appear only in online supplementary tables, and the trials were designed and funded by Vertex Pharmaceuticals.
Interrupted and repeated MAD cohorts
“The majority of treatment discontinuations occurred in two MAD cohorts of Study 2 and were due to sponsor decision (21 participants).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The inaxaplin 60 mg once daily and 90 mg once daily MAD cohorts in Study 2 were repeated with a distinct set of participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor funding and employment
“These studies were supported by Vertex Pharmaceuticals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Drs. Ogo Egbuna, George Manos, Simon Tian, and Fanuel Hagos are employees of Vertex Pharmaceuticals and own stock or stock options in the company.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
VX19-147-007
Objective
Location and study date
Study dates and status in the registry record
| Field | Registry entry |
|---|---|
| Recruitment status | “Completed” |
| Study start (actual) | “2023-06-12” |
| Primary completion (actual) | “2024-06-12” |
| Study completion (actual) | “2024-06-12” |
| First posted | “2023-05-18” |
| Last update posted | “2024-07-12” |
| Other study ID numbers | “VX19-147-007” |
Presentation at the NKF 2026 Spring Clinical Meetings
Study design
Design details in the registry record
| Field | Registry entry |
|---|---|
| Study type | “Interventional” |
| Phase | “Phase 1” |
| Primary purpose | “Basic Science” |
| Allocation | “Randomized” |
| Interventional model | “Sequential Assignment” |
| Masking | “None (Open Label)” |
Comparison with matched healthy participants
Eligibility criteria
Severe renal impairment not on dialysis
Age range and healthy volunteers
| Field | Registry entry |
|---|---|
| Ages eligible | “18 Years to 80 Years” |
| Sexes eligible | “All” |
| Accepts healthy volunteers | “Yes” |
Treatment
Study outcomes
Rationale for using plasma cmax and AUC0-inf as the primary endpoints
Registered primary and secondary outcomes
Renal clearance in the healthy-adult studies
“Renal clearance was a minor excretion pathway for inaxaplin; dose adjustments are therefore not anticipated for the intended patient population which will include patients with renal function impairment (online Table S2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment in the registry record
| Field | Registry entry |
|---|---|
| Enrollment (actual) | “16” |
Enrollment reported in the congress abstract
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Exposure in severe renal impairment compared with healthy matches
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Safety in the renal and hepatic impairment studies
Study limitations
Summary: study limitations
VX19-147-007 gave a single 45 mg dose to 16 participants: 8 with severe renal impairment (estimated glomerular filtration rate below 30 mL/min and not on dialysis) and 8 matched healthy participants. The results are available only as a congress abstract, which reports the geometric least squares mean ratio as “<120%” without point estimates or confidence intervals and reports safety only as “generally safe and well tolerated”. The ClinicalTrials.gov record lists no posted results. Participants on dialysis and multiple-dose exposure were not studied, and five of the six abstract authors list a Vertex Pharmaceuticals affiliation.
Author affiliations of the congress abstract
No results posted in the registry record
VX20-147-006
Objective
Location and study date
Study dates and status in the registry record
| Field | Registry entry |
|---|---|
| Recruitment status | “Completed” |
| Study start (actual) | “2024-08-02” |
| Primary completion (actual) | “2024-12-20” |
| Study completion (actual) | “2024-12-20” |
| First posted | “2024-07-31” |
| Last update posted | “2025-01-20” |
| Other study ID numbers | “VX20-147-006” |
Study locations in the registry record
“This study has 3 locations” (opens the source at this quote in a new tab)
“Miami, Florida, United States, 33136” (opens the source at this quote in a new tab)
“St. Petersburg, Florida, United States, 33705” (opens the source at this quote in a new tab)
“San Antonio, Texas, United States, 78215” (opens the source at this quote in a new tab)
Presentation at the NKF 2026 Spring Clinical Meetings
Study design
Phase 1, open-label, single-dose design with matched healthy participants
Design details in the registry record
| Field | Registry entry |
|---|---|
| Study type | “Interventional” |
| Phase | “Phase 1” |
| Primary purpose | “Basic Science” |
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |
Comparison with matched healthy participants
Eligibility criteria
Child-Pugh classes and matching of healthy participants
Key exclusion criteria in the registry record
Age range and healthy volunteers
| Field | Registry entry |
|---|---|
| Ages eligible | “18 Years to 75 Years” |
| Sexes eligible | “All” |
| Accepts healthy volunteers | “Yes” |
Treatment
Arms in the registry record
“Experimental: Cohort 1: Mild Hepatic Impairment” (opens the source at this quote in a new tab)
“Experimental: Cohort 2: Matched Healthy Participants” (opens the source at this quote in a new tab)
“Experimental: Cohort 3: Moderate Hepatic Impairment” (opens the source at this quote in a new tab)
“Experimental: Cohort 4: Matched Healthy Participants” (opens the source at this quote in a new tab)
“Tablet for oral administration.” (opens the source at this quote in a new tab)
Study outcomes
Rationale for using plasma cmax and AUC0-inf as the primary endpoints
Registered primary and secondary outcomes
Hepatic metabolism as the primary elimination pathway
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment in the registry record
| Field | Registry entry |
|---|---|
| Enrollment (actual) | “36” |
Enrollment reported in the congress abstract
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Exposure in mild or moderate hepatic impairment compared with healthy matches
Higher exposure in one participant with a Child-Pugh score of 9
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Safety in the renal and hepatic impairment studies
Study limitations
Summary: study limitations
VX20-147-006 gave a single 45 mg dose to 36 participants: 10 with mild (Child-Pugh 5 to 6) and 10 with moderate (Child-Pugh 7 to 9) hepatic impairment, and 16 matched healthy participants. The abstract's conclusion of no clinically meaningful difference extends only “up to and including a CP score of 7”; one participant with a Child-Pugh score of 9 had an AUC about 2.2-fold higher than participants with scores of 7 or below. Severe hepatic impairment (Child-Pugh Class C) was outside the eligibility criteria. The results are available only as a congress abstract, which reports the geometric least squares mean ratio as “<125%” without point estimates or confidence intervals, and the ClinicalTrials.gov record lists no posted results.
No results posted in the registry record
VX22-147-010
Objective
Location and study date
Study dates and status in the registry record
| Field | Registry entry |
|---|---|
| Recruitment status | “Completed” |
| Study start (actual) | “2023-07-19” |
| Primary completion (actual) | “2023-09-02” |
| Study completion (actual) | “2023-09-02” |
| First posted | “2023-07-21” |
| Last update posted | “2023-09-13” |
| Other study ID numbers | “VX22-147-010” |
Study design
Phase 1, open-label, randomized crossover design
Design details in the registry record
| Field | Registry entry |
|---|---|
| Study type | “Interventional” |
| Phase | “Phase 1” |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Masking | “None (Open Label)” |
Eligibility criteria
Age range and healthy volunteers
| Field | Registry entry |
|---|---|
| Ages eligible | “18 Years to 55 Years” |
| Sexes eligible | “All” |
| Accepts healthy volunteers | “Yes” |
Treatment
Three treatment sequences of test and reference tablets, fed and fasted
Study outcomes
Rationale for using relative bioavailability and food effect on cmax and AUC0-inf as the primary endpoints
Registered primary and secondary outcomes
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment in the registry record
| Field | Registry entry |
|---|---|
| Enrollment (actual) | “21” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
No evidence found.
Study limitations
Summary: study limitations
VX22-147-010 enrolled 21 healthy adults aged 18 to 55 years at one United States site and compared a test tablet with a reference tablet, and the test tablet fed with fasted, in a three-period crossover with 5-day washouts. The study was completed on 2023-09-02, but the ClinicalTrials.gov record lists no posted results, and no publication or congress abstract reporting its results was identified. The registry record does not state the dose or the composition of the test meal.